ABL Diagnostics (XPAR:ABLD) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 06, 2026)


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ABL Diagnostics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XPAR:ABLD vs VEEV, BTSG, TEM: Margin of Safety % (DCF Earnings Based) Comparison

For the Health Information Services subindustry, ABL Diagnostics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Diagnostics Margin of Safety % (DCF Earnings Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Margin of Safety % (DCF Earnings Based) falls into.


XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value